Q-omics provides the consensus-scored TTBK1 profile across patient tissues and cancer cell-line models. TTBK1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TTBK1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TTBK1 RNA expression shows 17,437 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight HNSC, and PCPG as cancer lineages where TTBK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTBK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTBK1 survival associations across molecular data types. TTBK1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTBK1 RNA expression–survival associations across cancer types. High TTBK1 expression shows unfavorable associations in UVM, MESO and DLBC, but favorable associations in HNSC, LIHC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TTBK1 RNA expression.
This table summarizes TTBK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TTBK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTBK1 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, BRCA, LUAD and LUSC. The HNSC box plot shows higher TTBK1 RNA expression in tumor versus normal tissue (log2 FC = +0.156, t-test p < 0.001).
This table shows molecular features associated with TTBK1 in patient tissues and cancer cell lines. In patient samples, TTBK1 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, TTBK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_SCLC.
